Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Developing a New Definition and Assessing New Clinical Criteria for Septic Shock

For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Manu Shankar-Hari, MD, MSc; Gary S. Phillips, MAS; Mitchell L. Levy, MD; Christopher W. Seymour, MD, MSc; Vincent X. Liu, MD, MSc; Clifford S. Deutschman, MD; Derek C. Angus, MD, MPh; Gordon D. Rubenfeld, MD, MSc; Mervyn Singer, MD, FRCP; for the Sepsis Definitions Task Force

IMPORTANCE Septic shock currently refers to a state of acute circulatory failure associated with infection. Emerging biological insights and reported variation in epidemiology challenge the validity of this definition.

OBJECTIVE To develop a new definition and clinical criteria for identifying septic shock in adults.

DESIGN, SETTING, AND PARTICIPANTS The Society of Critical Care Medicine and the European Society of Intensive Care Medicine convened a task force (19 participants) to revise current sepsis/septic shock definitions. Three sets of studies were conducted: (1) a systematic review and meta-analysis of observational studies in adults published between January 1, 1992, and December 25, 2015, to determine clinical criteria currently reported to identify septic shock and inform the Delphi process; (2) a Delphi study among the task force comprising 3 surveys and discussions of results from the systematic review, surveys, and cohort studies to achieve consensus on a new septic shock definition and clinical criteria; and (3) cohort studies to test variables identified by the Delphi process using Surviving Sepsis Campaign (SSC) (2005-2010; n = 28 150), University of Pittsburgh Medical Center (UPMC) (2010-2012; n = 1 309 025), and Kaiser Permanente Northern California (KPNC) (2009-2013; n = 1 847 165) electronic health record (EHR) data sets.

MAIN OUTCOMES AND MEASURES Evidence for and agreement on septic shock definitions and criteria.

RESULTS The systematic review identified 44 studies reporting septic shock outcomes (total of 166 479 patients) from a total of 92 sepsis epidemiology studies reporting different cutoffs and combinations for blood pressure (BP), fluid resuscitation, vasopressors, serum lactate level, and base deficit to identify septic shock. The septic shock–associated crude mortality was 46.5% (95% CI, 42.7%-50.3%), with significant between-study statistical heterogeneity (I^2 = 99.5%; τ^2 = 182.5; P < .001). The Delphi process identified hypotension, serum lactate level, and vasopressor therapy as variables to test using cohort studies. Based on these 3 variables alone or in combination, 6 patient groups were generated. Examination of the SSC database demonstrated that the patient group requiring vasopressors to maintain mean BP 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L (18 mg/dL) after fluid resuscitation had a significantly higher mortality (42.3% [95% CI, 41.2%-43.3%]) in risk-adjusted comparisons with the other 5 groups derived using either serum lactate level greater than 2 mmol/L alone or combinations of hypotension, vasopressors, and serum lactate level 2 mmol/L or lower. These findings were validated in the UPMC and KPNC data sets.

CONCLUSIONS AND RELEVANCE Based on a consensus process using results from a systematic review, surveys, and cohort studies, septic shock is defined as a subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. Adult patients with septic shock can be identified using the clinical criteria of hypotension requiring vasopressor therapy to maintain mean BP 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L after adequate fluid resuscitation.

JAMA. 2016;315(8):775-787. doi:10.1001/jama.2016.0289

Editorial page 757

Author Audio Interview at jama.com

Related articles pages 762 and 801

Supplemental content at jama.com

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: Members of the Sepsis Definitions Task Force are listed at the end of this article.

Corresponding Author: Manu Shankar-Hari, MD, MSc, Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, United Kingdom (manu.shankar-hari@kcl.ac.uk).

Consensus definitions, generated in 1991[1] and revisited in 2001,[2] describe septic shock as a state of cardiovascular dysfunction associated with infection and unexplained by other causes. The increasing availability of large electronic health record (EHR) data sets, registries, national case mix programs, trial data sets, and claims databases using *International Classification of Diseases* codes have since generated multiple observational studies reporting septic shock epidemiology. However, variable interpretation and application of the consensus definitions[1,2] have contributed to variable estimates of both incidence and outcomes.[3-8] It is unclear to what extent these variations represent true differences or an artifact attributable to inconsistent use of definitions.[8,9] Furthermore, emerging insights into sepsis pathophysiology[10-13] warrant a review of the current septic shock definition and the criteria used to identify it clinically.

Against this background, the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Med (ESICM) convened an international task force to review definitions of sepsis and septic shock in January 2014. To support the task force deliberations on redefining septic shock, a series of activities was performed: a systematic review and meta-analysis of criteria used in observational studies reporting sepsis epidemiology in adults; a Delphi study to achieve consensus; cohort studies using the Surviving Sepsis Campaign (SSC) registry; and subsequent testing of the applicability of the new criteria in patients with suspected infection from 2 large EHR-derived data sets. The aims of this study were to develop an updated septic shock definition and to derive clinical criteria for identifying patients with septic shock meeting this updated definition. Specifically, this updated definition and these criteria are intended to provide a standard classification to facilitate clinical care, future clinical research, and reporting.

Methods

In this article, "definition" refers to a description of septic shock and "clinical criteria" to variables used to identify adult patients with septic shock.

Task Force

The SCCM and ESICM each nominated cochairs of the task force and provided unrestricted funding support toward the work conducted. The 2 cochairs then selected 17 other task force participants based on their scientific expertise in sepsis epidemiology, clinical trials, and basic or translational research. Task force participants are listed at the end of the article. The task force retained complete autonomy for all decisions. ESICM and SCCM had no role in study design, conduct, or analysis but were consulted for peer review and endorsement of the manuscript.[14]

Systematic Review and Meta-analysis

The aims of the systematic review were to assess the different criteria used to identify adult patients with septic shock and whether these criteria were associated with differences in reported outcomes. MEDLINE was searched using search terms, MeSH headings, and combinations of *sepsis*, *septic shock*, and *epidemiology* and limits of human studies; adults 19 years or older; English-language publications; and publication dates between January 1, 1992 (1991 definitions[1]), and December 25, 2015. For full-text review, only noninterventional studies reporting sepsis epidemiology and all-cause mortality were included. Randomized clinical trials were excluded, because the additional inclusion and exclusion criteria might confound the effect of criteria on mortality (the study objective).[8] To avoid variability in outcomes related to specific pathogens, specific patient groups, and interventional before-and-after studies, studies reporting these populations were also excluded. Data were extracted on cohort recruitment period, cohort characteristics, setting, criteria used to identify septic shock, and acute mortality. Detailed methods, including search strategy, are presented in eMethods 1 and eTable 1 in the Supplement.

Delphi Study

To generate consensus on the septic shock definition and criteria, 3 face-to-face meetings, 3-round sequential pretested questionnaires, and email discussions among the task force participants were conducted. One task force member did not participate in these surveys because of lack of content expertise, and 1 did not respond to the first 2 surveys. Questionnaires were developed, refined, and administered consisting of single- and multiple-answer questions, free-text comments, and a 5-point Likert agreement scale. For consensus discussions and noting agreement, the 5-point Likert agreement scales were grouped at the tails of the scale choices (ie, "strongly disagree" grouped with "disagree"; "strongly agree" grouped with "agree"). All outputs from the systematic review, surveys, and the results of cohort studies were made available to participants throughout the Delphi study.

In the first round (August 2014), using 26 questions in 4 domains, agreement and opinions were explored on (1) components of the new septic shock definition; (2) variables and their cutoffs identified by the systematic review; (3) definitions of, and criteria for, hypotension, persistent hypotension, adequacy of resuscitation, and resuscitation end points; and (4) septic shock severity scoring. In the second round (November 2014), 4 questions were used to generate statements for key terms (persistent hypotension, adequacy of resuscitation, and septic shock) and to reach agreement on test variables and outcomes for subsequent analysis of predictive validity. The objectives of the third round (January 2015) were to establish a consensus definition of septic shock and related clinical criteria. In the third survey, the task force members were given 4 choices for the septic shock updated criteria ([1] serum lactate level alone; [2] hypotension alone; [3] vasopressor-dependent hypotension or serum lactate level; [4] vasopressor-dependent hypotension and serum lactate level) and were asked to provide their first and second choices. The cumulative first or second choices were used to agree on the reported septic shock criteria.

Questionnaire items were accepted if agreement exceeded 65%. Choices for which agreement was less than 65% were rediscussed to achieve consensus or were eliminated, as appropriate to achieve the project aims. The survey questionnaires are presented in eMethods 2 in the Supplement.

Cohort Studies

The institutional review boards of Cooper University Hospital (Camden, New Jersey),[15] University of Piitsburgh Medical Center (UPMC; a network of hospitals in western Pennsylvania), and Kaiser Permanente Northern California (KPNC)[16] provided ethics approvals for research using the SSC and EHR data sets, respectively.

The SSC registry includes data collected from 218 hospitals in 18 countries on 28 150 patients with suspected infection who, despite adequate fluid resuscitation as judged by the collecting sites, still had 2 or more systemic inflammatory response syndrome criteria and 1 or more organ dysfunction criteria (eMethods 3 in the Supplement). The SSC database setup, inclusion, and reporting items are described in detail elsewhere.[6,17] To select clinical criteria for the new septic shock definition, an analysis data set was created that included all patients with a serum lactate level measurement or a mean arterial pressure less than 65 mm Hg after fluids, or who received vasopressors.

For external validation, mortality was determined using the same clinical criteria in patients with suspected infection (cultures taken, antibiotics commenced) within 2 large EHR databases from UPMC (12 hospitals, 2010-2012, n = 1 309 025) and KPNC (20 hospitals, 2009-2013, n = 1 847 165). Three variables (hypotension, highest serum lactate level, and vasopressor therapy as a binary variable [yes/no]) were extracted from these 2 data sets during the 24-hour period after infection was suspected. Descriptive analyses, similar to those performed on the SSC data set, were then undertaken. Because of constraints on data availability, hypotension was considered present if systolic blood pressure was 100 mm Hg or less for any single measurement taken during the 24-hour period after infection was suspected. Serum lactate levels were measured in 9% of infected patients at UPMC and in 57% of those at KPNC after implementation of a sepsis quality improvement program.

Statistics

Meta-analysis

A random effects meta-analysis of septic shock mortality by study-specific septic shock criteria and sepsis definitions was performed. Two meta-regression models of septic shock mortality were tested with the covariates: sepsis definition, criteria for shock, mid-cohort-year of study population, single center or multicenter, and World Health Organization member state regions.[18] These 2 models (with and without per capita intensive care unit beds) were generated to account for international cohorts and countries for which per capita intensive care unit bed data were unavailable (See eMethods 1 in the Supplement for details).

Cohort Studies

Hospital mortality was used as the primary outcome for derivation and descriptive validation analysis. Using the 3 dichotomous variables identified in round 2 of the Delphi process, the SSC cohort was divided into 6 groups and the variables tested either alone or in combination: (1) hypotension (mean arterial pressure <65 mm Hg) after fluid administration; (2) vasopressor therapy; and (3) serum lactate level greater than 2 mmol/L or 2 mmol/L or less (to convert serum lactate values to mg/dL, divide by 0.111). Hypotension was assumed when vasopressor therapy was being administered, generating 6 distinct potential septic shock patient groups using the 3 selected variables (eTable 5 in the Supplement). Analyses were performed using either the 6 groups or the 3 dichotomous variables as the risk factor. Subsequent analyses using the serum lactate level as a categorical variable were performed using a χ^2 test of trend for mortality.

Currently, there are no gold standard septic shock criteria for predictive validity comparisons.[8] Thus, these analyses aimed to identify a patient population that has the attributes of the newly proposed definition, which includes higher mortality compared with other patient populations commonly reported as having septic shock in the literature identified by the systematic review. Therefore, the independent relationship between the 3 potential criterion variables (hypotension, serum lactate level, and vasopressor therapy) agreed on the second round of the Delphi process and a future outcome (hospital mortality) was tested using

Figure 1. Study Identification and Selection Process Used in the Systematic Review



[a] Nonduplicate references from other sources included review articles.[3,108-110] See eMethods 1 in the Supplement for further details of search strategy.

[b] Refers to records that were excluded after reference screening of full text articles. The screening criteria for full text inclusion were reporting of all case sepsis epidemiology in adult populations without specific assessment of interventions. The qualitative review assessed sepsis and septic shock definitions and criteria. The records included in the qualitative review (92 studies[5-7,19-107]) are presented in eTable 2 in the Supplement. The quantitative review assessed septic shock criteria and mortality.

[c] Refers to the records included for quantitative assessment of septic shock mortality and the heterogeneity by criteria using random-effects meta-analysis (44 studies[5-7,19-59]) (eTable 2 in the Supplement).

Table 1. Summary of Septic Shock Definitions and Criteria Reported in the Studies Identified by the Systematic Review[a]

Criteria	Septic Shock Case Definitions and Corresponding Variables Reported in Literature				Other Description of Criteria Variables
	Consensus Definitions		Other Definitions		
	Bone et al[1]	Levy et al[2]	SSC[111]	Trial-based[112]	
Infection	Suspected or proven	Suspected or proven	Suspected or proven	Suspected or proven	Bacteremia, culture positive; CDC definitions for infection
SIRS criteria, No.	2	One or more of 24 variables[b]	2	3	NA
Septic shock description	Sepsis-induced hypotension despite adequate resuscitation OR receiving vasopressors/Inotropes plus presence of perfusion abnormalities	State of acute circulatory failure characterized by persistent arterial hypotension after adequate resuscitation unexplained by other causes	Sepsis-induced hypotension persisting despite adequate fluid resuscitation	Cardiovascular dysfunction defined as hypotension despite adequate resuscitation or need for vasopressors	Precoded data using *ICD-9* and *ICD-10* codes[c]
Hypotension, mm Hg					
Systolic BP	<90	<90	<90	<90	<100
Decrease in systolic BP	Decrease >40	Decrease >40	Decrease >40	NA<70	>50% decrease in hypertension
MAP	No	<60	<70	Hypotension lasting >1 h after resuscitation	<65
Adequate resuscitation definition	Not defined	Not defined	Goals set as CVP 8-12 mm Hg; urine output ≥0.5 mL/kg/h; $ScvO_2$ >70%	Not defined	After resuscitation fluids (0.5 L; 1 L; 1.5 L; 20 mL/kg ideal body weight
Vasopressor use	Yes (not absolute requirement)	Yes (CVS SOFA score)	Yes (not absolute requirement)	Yes (not absolute requirement)	Vasoactive drugs required for >30 min
Hypoperfusion abnormalities	Hypoperfusion abnormality defined as lactic acidosis; oliguria; low Glasgow Coma Score	Tissue hypoperfusion defined as serum lactate >1 mmol/L or delayed capillary refill	Tissue hypoperfusion defined as infection-induced hypotension, elevated serum lactate (>4 mmol/L), or oliguria	No description	Serum lactate >2.5 mmol/L; base deficit >5 mEq/L, alkaline reserve <18 mEq/L; CVP <8; PCWP <12
Data points from included studies, No. (%)[d]	39 (75)		13 (25)		
Sample size, No.	158 354		8125		
Mortality by septic shock definition using random-effects meta analysis, % (95% CI)	47.2 (42.7-51.7)		44.2 (38.5-49.9)		
I^2, %[e]	99.6		95.9		
τ^2[f]	191.21		94.9		
P value heterogeneity	<.001		<.001		

Abbreviations: BP, blood pressure; CDC, Centers for Disease Control and Prevention; CVP, central venous pressure; CVS, cardiovascular system; *ICD*, *International Classification of Diseases*; MAP, mean arterial pressure; NA, not applicable; PCWP, pulmonary capillary wedge pressure; SBP, systolic blood pressure; $ScvO_2$, central venous oxygen saturation; SIRS, systemic inflammatory response syndrome; SOFA, Sequential [Sepsis-related] Organ Failure Assessment; SSC, Surviving Sepsis Campaign.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

[a] The summary table was generated from eTable 2 data from 92 studies.[5-7,19-107]

[b] Levy et al highlight an extended variable list as a replacement for SIRS criteria consisting of general (n = 7); inflammatory (n = 5); hemodynamic (n = 3); organ dysfunction (n = 7) and tissue perfusion (n = 2) variables.[2]

[c] Different *ICD-9* codes are reported to identify septic shock in the literature. These include shock without trauma code 785.50 with all subcodes (785.51, 785.52, 785.59), hypotension code 458 with subcodes (458.0, 458.8 458.9), cardiovascular failure code 427.5 and the nonspecific low blood pressure code 796.3.

[d] Studies reporting 2 or more subsets,[6,7,30,32] current study (whole population and Group 1), and GiViTI database account for 52 data points from 44 studies. See Figure 2 notes for further details.

[e] I^2 is the percentage of between-study heterogeneity that is attributable to a true variability in septic shock mortality, rather than sampling variation, implying heterogeneity.

[f] τ^2 refers to the between-study variance within groups in random-effects meta-analysis.

2 generalized estimating equation population-averaged logistic regression models with exchangeable correlation structure, where hospital site was the panel variable.

The first model used the potential septic shock groups 1 to 6 derived from these variables (eTable 5 in the Supplement), with group 1 as the referent group and adjusted for other covariates to assess true mortality difference between these groups. The second model assessed the independent association of these 3 potential criterion variables on hospital mortality adjusted for other covariates. These models also included an a priori adjustment variable for covariates including region (United States and Europe), location where sepsis was suspected (emergency department, ward, or critical care unit), antibiotic administration, steroid use, organ dysfunction (pulmonary, renal, hepatic, and acutely altered mental state), infection source (pneumonia, urinary tract infection, abdominal, meningitis and other), hyper-

Figure 2. Random-Effects Meta-analysis of Studies Identified in the Systematic Review, Reporting Septic Shock Mortality

Source	Septic Shock Deaths, No.	Patients With Septic Shock, No.	Mortality, % (95% CI)
Consensus Definition			
Degoricija et al,[46] 2006	90	125	72.0 (64.1-79.9)
Angkasekwinai et al,[38] 2007	41	78	52.6 (41.5-63.6)
Nesseler et al,[27] 2013	30	93	32.3 (22.8-41.8)
Sakr et al,[25] 2013	85	145	58.6 (50.6-66.6)
Goncalves-Pereira et al,[23] 2014	418	856	48.8 (45.5-52.2)
Leligdowicz et al,[5] 2014	4146	7974	52.0 (50.9 -53.1)
Ortiz et al,[19] 2014	144	319	45.1 (39.7-50.6)
Hypotension			
Laupland et al,[47] 2004	81	159	50.9 (43.2-58.7)
Gaspraovic et al,[45] 2006	44	129	34.1 (25.9-42.3)
Shapiro et al,[44] 2006	15	53	28.3 (16.2-40.4)
Povoa et al,[35] 2009	202	458	44.1 (39.6-48.7)
Klein Klowenberg et al,[7] 2012	52	98	53.1 (43.2-62.9)
Kaukonen et al,[22] 2014	14 609	51 079	28.6 (28.2-29.0)
Hypotension + Perfusion Abnormalities and/or Vasopressor Therapy			
Rangel-Frausto et al,[56] 1995	51	110	46.4 (37.0-55.7)
Salvo et al,[55] 1995	27	33	81.8 (68.7-95.0)
Alberti et al,[52] 2002	752	1180	63.8 (60.7-67.0)
Hypotension + Vasopressor Therapy			
Rodriguez et al,[31] 2001	129	283	45.6 (39.8-51.4)
Silva et al,[48] 2004	106	203	52.2 (45.3-59.1)
Laupland et al,[49] 2005	28	57	49.1 (36.5-61.8)
Vincent et al,[43] 2006	250	462	54.1 (49.6-58.7)
Karlsson et al,[40] 2007	90	363	24.8 (20.4-29.2)
Sakr et al,[39] 2007	250	462	54.1 (49.6-58.7)
Kauss et al,[34] 2010	185	255	72.5 (67.1-78.0)
Levy et al,[6] 2010	915	2494	36.7 (34.8-38.6)
Phua et al,[32] 2011	441	939	47.0 (44.3-49.7)
Ogura et al,[20] 2014	117	282	41.5 (35.7-47.2)
GiViTI database, 2015[a]	15 935	26 295	60.6 (60.0-61.2)
Hypotension + Vasopressor Therapy + Serum Lactate Level >2 mmol/L			
Group 1[b]	3602	8520	42.3 (41.2-43.3)
Hypotension + Perfusion Abnormalities + Vasopressor Therapy			
Lundberg et al,[54] 1998	19	41	46.3 (31.1-61.6)
Levy et al,[6] 2010	3428	7436	46.1 (45.0-47.2)
Quenot et al,[26] 2013	728	1495	48.7 (46.2-51.2)
Hypotension ± Vasopressor Therapy or Metabolic Abnormalities			
Peake et al,[36] 2009	75	324	23.1 (18.6-27.7)
Hypotension or Vasopressor Therapy			
Dahmash et al,[59] 1993	14	36	38.9 (23.0-54.8)
McLauchlan et al,[58] 1995	73	101	72.3 (63.5-81.0)
Pittet et al,[57] 1995	7	12	58.3 (30.4-86.2)
Schoenberg et al,[53] 1998	32	80	40.0 (29.3-50.7)
Engel et al,[42] 2007	119	190	62.6 (55.8-69.5)
Esteban et al,[41] 2007	27	59	45.8 (33.1-58.5)
Khwannimit and Bhuayanontachai,[37] 2009	164	303	54.1 (48.5-59.7)
Moore et al,[33] 2011	22	61	36.1 (24.0-48.1)
Zahar et al,[30] 2011 (community)	215	530	40.6 (36.3-44.8)
Zahar et al,[30] 2011 (ICU)	123	232	53.0 (47.1-59.0)
Zahar et al,[30] 2011 (nosocomial)	233	580	40.2 (36.1-44.2)
Klein Klowenberg et al,[7] 2012	29	47	61.7 (47.8-75.6)
Park et al,[28] 2012	228	740	30.8 (27.5-34.1)
Hypotension or Serum Lactate Any Value or Vasopressor Therapy			
Liu et al,[21] 2014	827	2536	32.6 (30.8-34.4)
SSC database,[16] 2016[b]	6556	18 840	34.8 (34.1-35.5)
***International Classification of Diseases* Codes**			
Annane et al,[51] 2003	13 269	26 172	50.7 (50.1-51.3)
Flaatten,[50] 2004	457	1562	29.3 (27.1-31.6)
Whittaker et al,[24] 2013	117	321	36.4 (31.2-41.7)
Serum Lactate Level >4 mmol/L			
Levy et al,[6] 2010	242	811	29.8 (26.7-33.0)
Phua et al,[32] 2011	219	466	47.0 (42.0-52.0)
Overall (I^2 = 99.5%; P = .000)			46.5 (42.7-50.3)



Forty-four studies report septic shock–associated mortality[5-7,19-59] and were included in the quantitative synthesis using random-effects meta-analysis. The Surviving Sepsis Campaign (SSC) database analyses with similar data are reported in 2 studies[6,29]; therefore, only one of these was used in the meta-analysis reported.[6] Levy et al report 3 septic shock subsets,[6] Klein Klowenberg et al report 2 (restrictive and liberal),[7] Zahar et al report 3 (community-acquired, ICU-acquired, and nosocomial infection–associated septic shock),[30] and Phua et al report 2 groups,[32] which were treated as separate data points in the meta-analysis. Studies under "consensus definition" cite the Sepsis Consensus Definitions.[1,2] The categorization used to assess heterogeneity does not fully account for septic shock details in individual studies.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

[a] Data obtained from GiViTI database provided by Bertolini et al (published 2015[8]).

[b] The mortality data of Group 1 patients (new septic shock population) and the overall potential septic shock patient populations (n = 18 840) described in the manuscript from the current study using the Surviving SSC database are also included in the meta-analysis. Septic shock–specific data were obtained from Australian & New Zealand Intensive Care Society Adult Patient Database (ANZICS), from a previously published report.[22] This results in 52 data points for random-effects meta-analysis.

thermia (>38.3°C), hypothermia (<36°C), chills with rigor, tachypnea (>20/min), leukopenia (<4000 cells/μL), hyperglycemia (plasma glucose level >120 mg/dL [6.7 mmol/L), platelet count <100 ×10^3/μL, and coagulopathy.

Table 2. Random Effects Meta-Analysis by Septic Shock Criteria Groups

Septic Shock Case Definition Criteria[a]	No.[b]	Mortality, No. of Events/ No. of Patients (%) [95% CI][c]	Heterogeneity Statistic[d]	df	*P* Value	I^2, %[e]	τ^{2f}
Consensus definitions cited (no description)	7	4954/9590 (51.6) [46.3-56.9]	53.2	6	<.001	88.7	39.9
Hypotension	6	15 003/51 976 (39.8) [30.1-49.5]	100.5	5	<.001	95.0	129.5
Hypotension + perfusion abnormalities and/or vasopressor therapy	3	830/1323 (63.3) [48.3-78.4]	20.4	2	<.001	90.2	155.8
Hypotension + vasopressor therapy	11	18 446/32 095 (48.9) [40.5-57.4]	919.8	10	<.001	98.9	195.8
Hypotension + vasopressor therapy + serum lactate level >2 mmol/L	1	3602/8520 (42.3) [41.2-43.3]		0			
Hypotension + perfusion abnormalities + vasopressor therapy	3	4175/8972 (47.0) [45.0-49.0]	3.4	2	.19	40.5	1.33
Hypotension ± vasopressor therapy or metabolic abnormalities	1	75/324 (23.1) [18.6-27.7]		0			
Hypotension or vasopressor therapy	13	1286/2971 (48.4) [41.3-55.5]	165.3	12	<.001	92.7	142.3
Hypotension or serum lactate any value or vasopressor therapy	2	7383/21 376 (33.9) [31.8-36.0]	4.9	1	.03	79.4	1.9
International Classification of Diseases codes	3	13 843/28 055 (38.9) [22.5-55.2]	343.8	2	<.001	99.4	205.6
Serum lactate level >4 mmol/L	2	461/1277 (38.3) [21.5-55.1]	32.6	1	.005	96.9	142.6
Overall	52	70 058/166 479 (46.5) [42.7-50.3]	11026.7	51	<.001	99.5	182.5

Abbreviation: df, degree of freedom.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

[a] Interpretation of the operationalization described for criteria to detect a septic shock case in individual studies reporting septic shock mortality.

[b] Number of data points from studies included in the systematic review shown in Figure 2 (see Figure 2 legend).

[c] Septic shock mortality was reported by 44 studies. Four studies report septic shock subsets[6,7,30,32]; data obtained from GiViTi database provided by Bertolini et al[8] and the current septic shock study resulting in 52 data points (further information provided in Figure 2 legend).

[d] The categorization used to assess heterogeneity does not fully account for septic shock details in individual studies.

[e] Percentage of between-study heterogeneity attributable to true variability in septic shock mortality, rather than sampling variation, implying heterogeneity.

[f] τ^2 refers to the between-study variance within groups in random-effects meta-analysis.

These models were used to estimate acute hospital mortality odds ratios (ORs) and adjusted ORs for mortality per-unit increase in the serum lactate level using continuous natural log-transformed serum lactate level. The operating characteristics (sensitivity/specificity over hospital mortality curves; positive and negative predictive values) of different serum lactate cutpoints (2, 3, and 4 mmol/L) were also tested using the logistic regression model. Multiple imputations (n = 20) were used to assess the statistical effect of missing serum lactate values.

$P < .05$ (2-sided) was considered statistically significant. All analyses were performed using Stata version 13.1 (StataCorp).

Results

Systematic Review and Meta-analysis

The systematic review identified 44 studies (166 479 patients) reporting septic shock mortality[5-7,19-59] from a total of 92 studies reporting sepsis cohorts between 1987 and 2015[5-7,19-107] (**Figure 1**; eTable 2 in the Supplement). Different shock criteria were used for systolic blood pressure (<90 mm Hg; <100 mm Hg; decrease >40 mm Hg; or decrease >50% of baseline value if hypertensive), mean arterial pressure (<70; <65; <60 mm Hg), serum lactate level (>4, >2.5, >2, >1 mmol/L) and base deficit (−5 mmol/L) (**Table 1**; eTable 2 in the Supplement). Temporal relationships between resuscitation status and end points to shock diagnosis were seldom reported. The studies differed in the description of resuscitation, persistent hypotension, and in their vasopressor definitions when using the cardiovascular Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score categories.[113] Diverse infection and organ dysfunction codes were also used in the *International Classification of Diseases*-based derivations.[63,70,79,90] Variables highlighted in Table 1 and in eTable 2 in the Supplement informed the Delphi survey questions.

The random-effects meta-analysis showed significant heterogeneity in septic shock mortality (mean mortality, 46.5% [95% CI, 42.7%-50.3%], with a near 4-fold variation from 23.0% to 81.8%; $I^2 = 99.5\%$; $\tau^2 = 182.5$; and $P < .001$) (**Figure 2**). Statistically significant heterogeneity was also observed in random-effects meta-analysis by clinical criteria reported for septic shock case definition in studies (**Table 2**). The meta-regression models described could not explain this heterogeneity (eTable 3A and eTable 3B in the Supplement).

Delphi Study

In the first round, informed by the systematic review, 15 task force members (88%) voted to include persistent hypotension, vasopressor therapy, and hyperlactatemia in the updated criteria. There was no agreement on the lower cutoff for serum lactate level in this round. Eleven members (65%) voted that including fluid resuscitation would improve the

Table 3. Distribution of Septic Shock Cohorts and Crude Mortality From Surviving Sepsis Campaign Database (n = 18 840 patients)

Cohorts[a]	Lactate Category, mmol/L[b]	No. (% of total) [n = 18 840]	Acute Hospital Mortality, No. (%) [95% CI]	χ^2 Test for Trend	Mortality, Adjusted OR (95% CI)[c]	*P* Value[c]
Group 1 (hypotensive after fluids and vasopressor therapy and serum lactate levels >2 mmol/L)						
	>2 to ≤3	2453 (13.0)	818 (33.3) [31.5-35.3]	<.001	1 [Reference]	
	>3 to ≤4	1716 (9.1)	621 (36.2) [33.9-38.5]			
	>4	4351 (23.1)	2163 (49.7) [48.2-51.2]			
	All	8520 (45.2)	3602 (42.3) [41.2-43.3]			
Group 2 (hypotensive after fluids and vasopressor therapy and serum lactate levels ≤2 mmol/L)	≤2	3985 (21.2)	1198 (30.1) [28.6-31.5]	NA[d]	0.57 (0.52-0.62)	<.001
Group 3 (hypotensive after fluids and no vasopressors and serum lactate levels >2 mmol/L)						
	>2 to ≤3	69 (0.4)	15 (21.7) [12.7-33.3]	.04	0.65 (0.47-0.90)	.009
	>3 to ≤4	57 (0.3)	14 (24.6) [14.1-37.8]			
	>4	97 (0.5)	35 (36.1) [26.6-46.5]			
	All	223 (1.2)	64 (28.7) [22.9-35.1]			
Group 4 (serum lactate levels >2 mmol/L and no hypotension after fluids and no vasopressors)						
	>2 to ≤3	860 (4.6)	179 (20.8) [18.1-23.7]	<.001	0.71 (0.62-0.82)	<.001
	>3 to ≤4	550 (2.9)	105 (19.1) [15.9-22.6]			
	>4	1856 (9.9)	555 (29.9) [27.8-32.0]			
	All	3266 (17.3)	839 (25.7) [24.2-27.2]			
Group 5 (serum lactate levels between 2-4 mmol/L and no hypotension before fluids and no vasopressors)						
	>2 to ≤3	1624 (8.6)	489 (30.1) [27.9-32.4]	NA[d]	0.77 (0.66-0.90)	.001
	>3 to ≤4	1072 (5.7)	313 (29.2) [26.5-32.0]			
	>4	790[e]				
	All	2696 (14.3)	802 (29.7) [28.0-31.5]			
Group 6 (hypotensive after fluids and no vasopressors and serum lactate ≤2 mmol/L)	≤2	150 (0.8)	28 (18.7) [12.8-25.8]	NA[d]	0.32 (0.20-0.51)	<.001

Abbreviations: NA, not available; OR, odds ratio.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

[a] Mean arterial pressure less than 65 mm Hg was used to define hypotension. "After fluids" was defined using the field "crystalloids" coded as a binary term within the Surviving Sepsis Campaign database.

[b] Using χ^2 tests, trends in mortality across serum lactate categories within groups (>2 to ≤3 mmol/L; >3 to ≤4 mmol/L and >4 mmol/L) were assessed.

[c] Refers to the adjusted OR generated using generalized estimating equation regression model (eTable7 in the Supplement).

[d] χ^2 test for trend could only be performed if there were 3 or more serum lactate categories.

[e] Excluded from full case analysis.

criteria. The task force determined that neither a severity grading for septic shock nor criteria for either adequacy of fluid resuscitation or persistent hypotension should be proposed because of the nonstandardized use of hemodynamic monitoring, resuscitation protocols, and vasopressor dosing in clinical practice. (Other results are reported in eTable 4 in the Supplement.)

In Delphi round 2, the task force was provided with a preliminary descriptive analysis from the SSC database. With agreement on the description of the septic shock illness concept, 3 test variables (hypotension after fluid resuscitation, vasopressor therapy, and serum lactate level) were agreed on for predictive validity analyses. The "after fluids" field in the SSC database was used as a proxy for resuscitation. The need for vasopressors was agreed as a proxy for persistent hypotension by 95% of the task force. Twelve members (71%) voted that a minimum vasopressor dose should not be proposed in view of the variability in blood pressure targets and resuscitation protocols identified by the systematic review, and because of variable sedation use. Vasopressor therapy was therefore treated as a binary variable within the analysis. To derive an optimal cutoff for serum lactate level, 13 task force members (77%) agreed on acute hospital mortality as the outcome variable. The test variables could be present either alone or in combinations, thus identifying 6 potential groups of patients with septic shock (**Table 3**; eTable 5 in the Supplement).

Prior to the final round of the Delphi process, all analyses from the SSC data set and the EHR data sets were provided. These findings generated the new definition—"septic shock is defined as a subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone"—and the clinical criteria described below.

Cohort Studies

SSC Database

Patients with serum lactate levels greater than 4 mmol/L who did not receive fluids as recommended by the SSC guidelines[111] (n = 790 [2.8%]) were excluded. Patients without any serum lactate values measured were excluded initially for full case analysis (n = 4419 [15.7%]) but were reassessed in the missing data analysis. Of the 22 941 remaining patients, 4101 coded as having severe sepsis were excluded from this analysis, generating the analysis set of 18 840 patients who were either hy-

Figure 3. Selection of Surviving Sepsis Campaign Database Cohort



Hypotension was defined as mean arterial pressure less than 65 mm Hg. Vasopressor therapy to maintain mean arterial pressure of 65 mm Hg or higher is treated as a binary variable. Serum lactate level greater than 2 mmol/L (18 mg/dL) is considered abnormal. The "after fluids" field in the Surviving Sepsis Campaign (SSC) database was considered equivalent to adequate fluid resuscitation. "Before fluids" refers to patients who did not receive fluid resuscitation. Serum lactate level greater than 2 mmol/L after fluid resuscitation but without hypotension or need for vasopressor therapy (group 4) is defined as "cryptic shock." Missing serum lactate level measurements (n = 4419 [15.7%]) and patients with serum lactate levels greater than 4 mmol/L (36 mg/dL) who did not receive fluids as per SSC guidelines (n = 790 [2.8%]) were excluded from full case analysis. Of the 22 941 patients, 4101 who were coded as having severe sepsis were excluded. Thus, the remaining 18 840 patients were categorized within septic shock groups 1 to 6.

[a]Patients with screening serum lactate levels coded as greater than 2 mmol/L (n=3342) were included in the missing-data analysis.

potensive after fluids or required vasopressors or had a serum lactate level measurement (**Figure 3** and Table 3). Hypotension was reported in 83.1%, serum lactate level greater than 2 mmol/L in 78.1%, and receipt of vasopressors in 66.4%. Overall, crude hospital mortality was 34.7%. Cohort characteristics by setting are shown in eTable 6 in the Supplement.

Predictive Validity of Potential Septic Shock Groups

Of the 6 groups of potential patients with septic shock (Table 3), the most prevalent was group 1 (hypotension + vasopressor therapy + serum lactate level >2 mmol/L) (n = 8520); followed by groups 2 (n = 3985) and 4 (n = 3266). Crude hospital mortality rates in these 3 groups were 42.3%, 30.1%, and 25.7%, respectively. Statistically significant increasing trends in crude mortality were observed over increasing serum lactate level categories within groups (χ^2 test of trend: $P < .001$ for groups 1 and 4, $P = .04$ for group 3). The adjusted OR for hospital mortality using group 1 for reference was significantly lower in all other groups ($P < .01$ for groups 2 to 6), suggesting that group 1 represents a distinct subpopulation with a significantly greater risk of death (eTable 7 in the Supplement). By a majority (cumulative first choice, 72.2%; second choice, 55.6%) (eTable 4 in the Supplement), the task force agreed that group 1 was most consistent with the proposed septic shock definition, thus generating the new septic shock criteria.

Derivation of Serum Lactate Cutoff Value and Missing Data Analysis

In the generalized estimating equation model (shown in eTable 8 in the Supplement), serum lactate level was associated with mortality, and the adjusted OR for hospital mortality increased linearly with increasing serum lactate level. An increase in serum lactate level from 2 to 10 mmol/L increased the adjusted OR for hospital mortality from 1.4 (95% CI, 1.35-1.45) to 3.03 (95% CI, 2.68-3.45) (referent lactate = 1; **Figure 4**). A serum lactate level greater than 2 mmol/L was chosen as the preferred cutoff value for the new septic shock criteria, the rationale being the trade-off between highest sensitivity (82.5% when using the n = 18 840 subset, and 74.9% when using patients in groups 1 and 2 combined [n = 12 475]), and the decision from the Delphi process to identify the lowest serum lactate level independently associated with a greater risk of death (OR of 1.4 at a lactate value of 2 mmol/L) (**Table 4**; eTable 9, eFigure 1, and eFigure 2 in the Supplement).

Predicated on this understanding of the SSC database structure and the regression analyses completed (eTable 6, eTable 7, and eTable 8 in the Supplement), we assumed that data were missing at random; ie, any difference between observed values and missing values did not depend on unobserved data. Complete case analysis was therefore performed, followed by multiple imputation analysis to support the missing-at-random assumption.[114] The ORs for mortality per unit in-

crease in serum lactate level using complete case analysis (n = 18 840) and imputed analyses (n = 22 182) were similar (1.09 [95% CI, 1.08-1.10]; $P < .001$ vs 1.09 [95% CI, 1.08-1.09]; $P < .001$, respectively). The imputed and complete case analysis probabilities of hospital mortality were also similar (36.4% and 35.5%, respectively).

EHR Data Sets

The UPMC and KPNC EHRs included 148 907 and 321 380 adult patients with suspected infection, respectively (eTable 10 in the Supplement). Forty-six percent (n = 5984) of UPMC patients and 39% (n = 54 135) of KPNC patients with 1 or more SOFA score points and suspected infection fulfilled criteria for 1 of the 6 potential septic shock groups described. Patients meeting group 1 criteria (hypotension + vasopressor therapy + serum lactate level >2 mmol/L) comprised 5.3% (UPMC) and 14.9% (KPNC) of the EHR population of patients with suspected infection and had a mortality of 54% and 35%, respectively. Similar to the SSC database, crude mortality rates within each group were higher among those with higher serum lactate levels (**Table 5**).

Discussion

The systematic review illustrated the variability in criteria currently used to identify septic shock, whereas the meta-analysis demonstrated the heterogeneity in mortality. Informed by this systematic review, a Delphi process was used to reach a consensus definition of septic shock and related clinical criteria. Three large data sets were then used to determine the predictive validity of these criteria. Septic shock was defined as a subset of sepsis in which circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. The clinical criteria representing this definition were the need for vasopressor therapy to maintain a MAP of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L persisting after fluid resuscitation.

The proposed definition and criteria of septic shock differ from prior definitions[1,2,111] in 2 respects: (1) the need for both a serum lactate level and vasopressor-dependent hypotension (ie, cardiovascular SOFA score ≥2) instead of either alone and (2) a lower serum lactate level cutoff of 2 mmol/L vs

Figure 4. Serum Lactate Level Analysis



Adjusted odds ratio for actual serum lactate levels for the entire septic shock cohort (N = 18 840). The covariates used in the regression model include region (United States and Europe), location where sepsis was suspected (emergency department, ward, or critical care unit), antibiotic administration, steroid use, organ failures (pulmonary, renal, hepatic, and acutely altered mental state), infection source (pneumonia, urinary tract infection, abdominal, meningitis, and other), hyperthermia (>38.3°C), hypothermia (<36°C), chills with rigor, tachypnea (>20/min), leukopenia (<4000 cells/μL), hyperglycemia (plasma glucose >120 mg/dL [6.7 mmol/L]), platelet count <100 ×10^3/μL, and coagulopathy (eMethods 3 in the Supplement). The adjusted odds ratio (OR) for the 6 groups presented in eTable 7 in the Supplement and the adjusted OR for the individual variables (lactate, vasopressor therapy, and fluids) are reported in eTable 8 in the Supplement. To convert serum lactate values to mg/dL, divide by 0.111.

Table 4. Characteristics of Serum Lactate Level Cutoff Values for Complete Case Analysis and Imputation Analysis Using Surviving Sepsis Campaign Database

	Serum Lactate Level, mmol/L					
	>2		>3		>4	
Characteristic	Died/Total	% (95% CI)	Died/Total	% (95% CI)	Died/Total	% (95% CI)
Complete Case Analysis (n = 18 795)						
Hospital mortality, %	5757/18 795	30.6 (29.9-31.4)	6101/18 795	32.5 (31.8-33.2)	6456/18 975	34.3 (33.7-35.0)
Sensitivity, %	5372/6509	82.5 (81.6-83.4)	3779/6509	58.1 (56.8-59.3)	2811/6509	43.2 (42.0-44.4)
Specificity, %	2748/12 286	22.4 (21.6-23.1)	6418/12 286	52.2 (51.4-53.1)	8564/12 286	69.7 (68.9-70.5)
PPV, %	5372/14 910	36.0 (35.3-36.8)	3779/9647	39.2 (38.2-40.2)	2811/6533	43.0 (41.8-44.2)
NPV, %	2748/3885	70.7 (69.3-72.2)	6418/9148	70.1 (69.2-71.1)	8564/12 286	69.8 (69.0-70.7)
Imputed Missing Serum Lactate Level (n = 22 182)						
Hospital mortality, %	6965/22 182	31.4 (30.8-32.0)	7363/22 182	33.2 (32.6-33.8)	7772/22 182	35.0 (34.4-35.7)
Sensitivity, %	6457/7748	83.3 (82.5-84.2)	4461/7748	57.6 (56.5-58.7)	2931/7748	37.8 (36.7-38.9)
Specificity, %	3341/14 434	23.1 (22.5-23.8)	7833/14 434	54.3 (53.5-55.1)	10 801/14 434	74.8 (74.1-75.5)
PPV, %	6457/17 550	36.8 (36.1-37.5)	4461/11 062	40.3 (39.4-41.2)	2931/6564	44.6 (43.4-45.8)
NPV, %	3341/4634	72.1 (70.8-73.4)	7833/11 120	70.4 (69.6-71.3)	10 801/15 618	69.2 (68.4-69.9)

Abbreviations: NPV, negative predictive value; PPV, positive predictive value.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

Table 5. Crude Mortality in Septic Shock Groups From UPMC and KPNC Data sets

Variable[a]	Highest Serum Lactate Levels 24 h After Infection Identified, mmol/L	UPMC			KPNC		
		No. (%) (n = 5984)	Acute Hospital Mortality		No. (%) (n = 54 135)	Acute Hospital Mortality	
			No.	% (95% CI)		No.	% (95% CI)
Group 1	>2 (all)	315 (5.3)	171	54.3 (48.6-59.9)	8051 (14.9)	2835	35.2 (34.2-36.3)
	>3	246 (4.1)	147	59.8 (53.3-65.9)	6006 (11.1)	2355	39.2 (38.0-40.5
	>4	189 (3.2)	120	63.5 (56.2-70.4)	4438 (8.2)	1939	43.7 (42.2-45.2)
Group 2	≤2	147 (2.5)	37	25.2 (18.4-33.0)	3094 (5.7)	582	18.8 (17.4-20.2)
Group 3	>2 (all)	3544 (59.2)	1278	36.1 (34.5-37.7)	12 781 (23.6)	2120	16.6 (15.9-17.2)
	>3	2492 (41.6)	1058	42.5 (40.5-44.4)	6417 (11.9)	1381	21.5 (20.5-22.5)
	>4	1765 (29.5)	858	48.6 (46.3-51.0)	3316 (6.1)	914	27.6 (26.0-29.1)
Groups 4 and 5	>2 (all)	1978 (33.1)	355	17.9 (16.3-19.7)	30 209 (55.8)	2061	6.8 (6.5-7.1)
	>3	1033 (17.3)	224	21.7 (19.2-24.3)	12 450 (23.0)	1138	9.1 (8.6-9.7)
	>4	566 (9.4)	146	25.8 (22.2-29.6)	5394 (9.9)	637	11.8 (11.0-12.7)

Abbreviations: KPNC, Kaiser Permanente Northern California; SSC, Surviving Sepsis Campaign; UPMC, University of Pittsburgh Medical Center.

SI conversion factor: To convert serum lactate values to mg/dL, divide by 0.111.

[a] Group 1 refers to patients with hypotension + vasopressors + serum lactate levels greater than 2 mmol/L. Group 2 refers to patients with hypotension + vasopressors + serum lactate levels less than 2 mmol/L. Group 3 refers to patients with hypotension and serum lactate levels greater than 2 mmol/L. Groups 4 and 5 refer to isolated serum lactate level greater than 2 mmol/L. Counts within a group are not mutually exclusive, as those with serum lactate levels greater than 2 mmol/L will include those in the higher serum lactate cutoffs.

4 mmol/L as currently used in the SSC definitions. In the new septic shock definition, an increase in serum lactate level is positioned as a proxy for a cellular metabolic abnormality, and as a variable independently associated with acute mortality (predictive validity), which is consistent with the published literature.[115-118] An elevated serum lactate level is not specific for cellular dysfunction in sepsis[118,119] but has face validity given the lack of a superior yet readily available alternative. This present study identifies a lower serum lactate level cutoff as an independent prognostic variable when compared with a recent analysis of the entire SSC database. This disparity is explained by using a data set of 18 840 patients in the analysis in this study rather than the total 28 150-patient SSC data set used by Casserly et al.[17] From this subpopulation 6 groups were identified and analyzed as risk strata within the generalized estimating equation model and performance-tested for various serum lactate level cutoffs. The group with a significantly greater risk of death was then selected. In contrast, Casserly et al[17] reported the independent relationship of hypotension and serum lactate levels with mortality in severe sepsis.

The 6 potential septic shock patient groups analyzed in this study also provide an explanation for the heterogeneity in septic shock mortality highlighted by the meta-analysis. Depending on the group selected, septic shock mortality ranged from 12.8% to 51.2% within the SSC data set and from 7.0% to 64.0% in the EHR data sets. The KPNC EHR data set corroborated the consistent trends of higher mortality associated with a higher serum lactate level, even in a population with a wider range of illness severity captured by more prevalent measurement of serum lactate levels.

The key strengths of the present study are in the methodology used to arrive at the new definition and clinical criteria for septic shock, a clinical syndrome with a range of signs, symptoms, and biochemical abnormalities that are not pathognomonic. Furthermore, the supporting studies (systematic review, Delphi process, and analyses of the SSC and EHR cohorts) were iterative and concurrent with the consensus process, a significant step forward from previous definitions.

This study also has several limitations. First, the systematic review did not formally assess study quality and was restricted to MEDLINE publications, adult populations, and observational studies reporting epidemiology. Second, only the Delphi-derived variables were tested in multiple data sets to generate the proposed septic shock criteria. Other variables, including tissue perfusion markers (eg, base deficit, oliguria, acute alteration in mentation), blood pressure characteristics (eg, diastolic pressure), resuscitation end points (eg, central venous saturation, lactate clearance), and numerous biomarkers reported in the literature,[17] could potentially improve on the proposed septic shock criteria but were not included. However, operationalizing the definition of septic shock with 3 commonly measured variables should increase both generalizability and clinical utility. Third, the lack of a gold standard diagnostic criteria for septic shock[8] precludes comparative assessment of these proposed criteria. Fourth, all data sets had missing data that could potentially introduce a form of selection bias.[120] In the primary data set (SSC database) this issue was addressed by demonstrating that full case analysis is an appropriate method (see "Derivation of Serum Lactate Cutoff Value and Missing Data Analysis"). Fifth, serum lactate measurements are not universally available, especially outside of a critical care setting or in resource-limited environments. Although feasibility is a quality indicator for a definition,[8] identification of a critically ill patient would generally trigger obtaining a serum lactate measurement, both to stratify risk and to monitor the response to treatment.[17] Sixth, although the proposed new definition and clinical criteria for sepsis are arbitrary, these do have predictive validity for mortality, alongside face and content validity.[8]

This study represents one step in an ongoing iterative process and provides a resourceful structure and a predictive validity standard for future investigations in this area. Prospective validation of the clinical criteria may improve on the variables and cutoffs proposed herein, and identification and

validation of novel markers of organ dysfunction and shock may replace lactate level.[8]

Conclusions

Based on a consensus process using results from a systematic review, surveys, and cohort studies, septic shock is defined as a subset of sepsis in which underlying circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. Adult patients with septic shock can be identified using the clinical criteria of hypotension requiring use of vasopressors to maintain mean blood pressure of 65 mm Hg or greater and having a serum lactate level greater than 2 mmol/L persisting after adequate fluid resuscitation.

ARTICLE INFORMATION

Author Affiliations: Division of Asthma, Allergy, and Lung Biology, King's College London, London, United Kingdom (Shankar-Hari); Department of Critical Care Medicine, Guy's and St Thomas' NHS Foundation Trust, London SE17EH, United Kingdom (Shankar-Hari); The Ohio State University College of Medicine, Department of Biomedical Informatics, Center for Biostatistics, Columbus (Phillips); Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island (Levy); Clinical Research, Investigation, and Systems Modeling of Acute Illness Center, Department of Critical Care and Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania (Seymour, Angus); Division of Research, Kaiser Permanente, Oakland, California (Liu); Department of Pediatrics, Hofstra-North Shore-Long Island Jewish-Hofstra School of Medicine, Steven and Alexandra Cohen Children's Medical Center, New Hyde Park, New York (Deutschman); Department of Molecular Medicine, Hofstra-North Shore-Long Island Jewish-Hofstra School of Medicine, Steven and Alexandra Cohen Children's Medical Center, New Hyde Park, New York (Deutschman); Feinstein Institute for Medical Research, Manhasset, New York (Deutschman); Associate Editor, *JAMA* (Angus); Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada (Rubenfeld); Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (Rubenfeld); Bloomsbury Institute of Intensive Care Medicine, University College London, London, United Kingdom (Singer).

Author Contributions: Dr Shankar-Hari had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Shankar-Hari, Levy, Deutschman, Angus, Rubenfeld, Singer.
Acquisition, analysis, or interpretation of data: Shankar-Hari, Phillips, Levy, Seymour, Liu, Singer.
Drafting of the manuscript: Shankar-Hari, Phillips, Levy, Deutschman, Angus, Singer.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Shankar-Hari, Phillips, Seymour, Liu.
Obtained funding: Levy.
Administrative, technical, or material support: Shankar-Hari, Levy, Deutschman, Angus.
Study supervision: Seymour, Deutschman, Singer.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Shankar-Hari and Singer reported receiving support from the UK NIHR Biomedical Research Centre schemes. Dr Levy reported receiving a grant from ImmuneExpress. Dr Seymour reported receiving personal fees from Beckman Coulter. Dr Liu reported receiving K grant support from the National Institutes of Health (K23GM112018). Dr Deutschman reported holding patents on materials not related to this work and receiving travel/accommodations and related expenses for participation in meetings paid by the Centers for Disease Control and Prevention, World Federation of Societies of Intensive and Critical Care, Pennsylvania Assembly of Critical Care Medicine/PA Chapter, Society of Critical Care Medicine (SCCM)/Penn State–Hershey Medical Center, Society of Critical Care Medicine, Northern Ireland Society of Critical Care Medicine, International Sepsis Forum, Department of Anesthesiology, Stanford University, Acute Dialysis Quality Initiative, and European Society of Intensive Care Medicine (ESICM). Dr Singer reported serving on advisory boards for Bayer and Biotest and that he is a recipient of a UK NIHR Senior Investigator Fellowship (2009-2017). No other disclosures were reported.

Members of the Sepsis Definitions Task Force and Delphi Study: Derek Angus, Djilalli Annane, Michael Bauer, Rinaldo Bellomo, Gordon Bernard, Jean-Daniel Chiche, Craig Coopersmith, Cliff Deutschman (cochair), Richard Hotchkiss, Mitchell Levy, John Marshall, Greg Martin, Steve Opal, Gordon Rubenfeld, Christopher Seymour (co-opted), Manu Shankar-Hari (co-opted), Mervyn Singer (cochair), Tom van der Poll, Jean-Louis Vincent.

Funding/Support: The Sepsis Definitions Task Force received unrestricted funding support from the European Society of Intensive Care Medicine and the Society of Critical Care Medicine (sponsors).

Role of the Funders/Sponsors: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Dr Angus, *JAMA* Associate Editor, had no role in the evaluation of or decision to publish this article.

REFERENCES

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest*. 1992;101(6):1644-1655.

2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med*. 2003;31(4):1250-1256.

3. Rhee C, Gohil S, Klompas M. Regulatory mandates for sepsis care—reasons for caution. *N Engl J Med*. 2014;370(18):1673-1676.

4. Iwashyna TJ, Angus DC. Declining case fatality rates for severe sepsis. *JAMA*. 2014;311(13):1295-1297.

5. Leligdowicz A, Dodek PM, Norena M, et al. Association between source of infection and hospital mortality in patients who have septic shock. *Am J Respir Crit Care Med*. 2014;189(10):1204-1213.

6. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. *Intensive Care Med*. 2010;36(2):222-231.

7. Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. *Intensive Care Med*. 2012;38(5):811-819.

8. Shankar-Hari M, Bertolini G, Brunkhorst FM, et al. Judging quality of current septic shock definitions and criteria. *Crit Care*. 2015;19(1):445.

9. Iwashyna TJ, Govindan S. Did they just prove that a diagnosis of "septic shock" is meaningless? *Am J Respir Crit Care Med*. 2014;189(10):1156-1157.

10. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. *Virulence*. 2014;5(1):66-72.

11. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression. *Nat Rev Immunol*. 2013;13(12):862-874.

12. Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. *Am J Respir Crit Care Med*. 2013;187(5):509-517.

13. Rudiger A, Dyson A, Felsmann K, et al. Early functional and transcriptomic changes in the myocardium predict outcome in a long-term rat model of sepsis. *Clin Sci (Lond)*. 2013;124(6):391-401.

14. Singer M, Deutschman C, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. doi:10.1001/jama.2016.0287.

15. US Department of Health and Human Services (DHHS). Frequently Asked Questions About Human Research. DHHS website. http://www.hhs.gov/ohrp/policy/faq/index.html. May 10, 2010. Accessed Feburary 1, 2016.

16. Seymour CW, Liu V, Iwashyna TJ et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. doi:10.1001/jama.2016.0288.

17. Casserly B, Phillips GS, Schorr C, et al. Lactate measurements in sepsis-induced tissue hypoperfusion. *Crit Care Med*. 2015;43(3):567-573.

18. World Health Organisation (WHO). Health Statistics and Information Systems: Definition of Region Groupings. WHO website. http://www.who.int/healthinfo/global_burden_disease/definition_regions/en/. July 5, 2015.

19. Ortíz G, Dueñas C, Rodríguez F, et al. Epidemiology of sepsis in Colombian intensive care units. *Biomedica*. 2014;34(1):40-47.

20. Ogura H, Gando S, Saitoh D, et al. Epidemiology of severe sepsis in Japanese intensive care units. *J Infect Chemother*. 2014;20(3):157-162.

21. Liu V, Escobar GJ, Greene JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. *JAMA*. 2014;312(1):90-92.

22. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. *JAMA*. 2014;311(13):1308-1316.

23. Gonçalves-Pereira J, Pereira JM, Ribeiro O, et al. Impact of infection on admission and of the process of care on mortality of patients admitted to the intensive care unit: the INFAUCI study. *Clin Microbiol Infect*. 2014;20(12):1308-1315.

24. Whittaker SA, Mikkelsen ME, Gaieski DF, Koshy S, Kean C, Fuchs BD. Severe sepsis cohorts derived from claims-based strategies appear to be biased toward a more severely ill patient population. *Crit Care Med*. 2013;41(4):945-953.

25. Sakr Y, Elia C, Mascia L, et al. Epidemiology and outcome of sepsis syndromes in Italian ICUs. *Minerva Anestesiol*. 2013;79(9):993-1002.

26. Quenot JP, Binquet C, Kara F, et al. The epidemiology of septic shock in French intensive care units. *Crit Care*. 2013;17(2):R65.

27. Nesseler N, Defontaine A, Launey Y, Morcet J, Mallédant Y, Seguin P. Long-term mortality and quality of life after septic shock. *Intensive Care Med*. 2013;39(5):881-888.

28. Park DW, Chun BC, Kim JM, et al. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock. *J Korean Med Sci*. 2012;27(11):1308-1314.

29. Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe. *Lancet Infect Dis*. 2012;12(12):919-924.

30. Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock [published correction appears in *Crit Care Med*. 2011;39(10):2392]. *Crit Care Med*. 2011;39(8):1886-1895.

31. Rodríguez F, Barrera L, De La Rosa G, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. *Crit Care Med*. 2011;39(7):1675-1682.

32. Phua J, Koh Y, Du B, et al. Management of severe sepsis in patients admitted to Asian intensive care units. *BMJ*. 2011;342:d3245.

33. Moore LJ, McKinley BA, Turner KL, et al. The epidemiology of sepsis in general surgery patients. *J Trauma*. 2011;70(3):672-680.

34. Kauss IA, Grion CM, Cardoso LT, et al. The epidemiology of sepsis in a Brazilian teaching hospital. *Braz J Infect Dis*. 2010;14(3):264-270.

35. Póvoa PR, Carneiro AH, Ribeiro OS, Pereira AC; Portuguese Community-Acquired Sepsis Study Group. Influence of vasopressor agent in septic shock mortality. *Crit Care Med*. 2009;37(2):410-416.

36. Peake SL, Bailey M, Bellomo R, et al. Australasian resuscitation of sepsis evaluation (ARISE). *Resuscitation*. 2009;80(7):811-818.

37. Khwannimit B, Bhurayanontachai R. The epidemiology of, and risk factors for, mortality from severe sepsis and septic shock in a tertiary-care university hospital setting. *Epidemiol Infect*. 2009;137(9):1333-1341.

38. Angkasekwinai N, Rattanaumpawan P, Thamlikitkul V. Epidemiology of sepsis in Siriraj Hospital 2007. *J Med Assoc Thai*. 2009;92(suppl 2):S68-S78.

39. Sakr Y, Vincent JL, Schuerholz T, et al. Early- versus late-onset shock in European intensive care units. *Shock*. 2007;28(6):636-643.

40. Karlsson S, Varpula M, Ruokonen E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. *Intensive Care Med*. 2007;33(3):435-443.

41. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. *Crit Care Med*. 2007;35(5):1284-1289.

42. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany. *Intensive Care Med*. 2007;33(4):606-618.

43. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med*. 2006;34(2):344-353.

44. Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. *Ann Emerg Med*. 2006;48(5):583-590.

45. Gasparović V, Gornik I, Ivanović D. Sepsis syndrome in Croatian intensive care units: piloting a national comparative clinical database. *Croat Med J*. 2006;47(3):404-409.

46. Degoricija V, Sharma M, Legac A, et al. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital. *Croat Med J*. 2006;47(3):385-397.

47. Laupland KB, Zygun DA, Doig CJ, et al. One-year mortality of bloodstream infection-associated sepsis and septic shock among patients presenting to a regional critical care system. *Intensive Care Med*. 2005;31(2):213-219.

48. Silva E, Pedro MdeA, Sogayar AC, et al. Brazilian Sepsis Epidemiological Study (BASES study). *Crit Care*. 2004;8(4):R251-R260.

49. Laupland KB, Davies HD, Church DL, et al. Bloodstream infection-associated sepsis and septic shock in critically ill adults. *Infection*. 2004;32(2):59-64.

50. Flaatten H. Epidemiology of sepsis in Norway in 1999. *Crit Care*. 2004;8(4):R180-R184.

51. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B; CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network. *Am J Respir Crit Care Med*. 2003;168(2):165-172.

52. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. *Intensive Care Med*. 2002;28(2):108-121.

53. Schoenberg MH, Weiss M, Radermacher P. Outcome of patients with sepsis and septic shock after ICU treatment. *Langenbecks Arch Surg*. 1998;383(1):44-48.

54. Lundberg JS, Perl TM, Wiblin T, et al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. *Crit Care Med*. 1998;26(6):1020-1024.

55. Salvo I, de Cian W, Musicco M, et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. *Intensive Care Med*. 1995;21(suppl 2):S244-S249.

56. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). *JAMA*. 1995;273(2):117-123.

57. Pittet D, Rangel-Frausto S, Li N, et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock. *Intensive Care Med*. 1995;21(4):302-309.

58. McLauchlan GJ, Anderson ID, Grant IS, Fearon KC. Outcome of patients with abdominal sepsis treated in an intensive care unit. *Br J Surg*. 1995;82(4):524-529.

59. Dahmash NS, Chowdhury NH, Fayed DF. Septic shock in critically ill patients. *J Infect*. 1993;26(2):159-170.

60. Whittaker SA, Fuchs BD, Gaieski DF, et al. Epidemiology and outcomes in patients with severe sepsis admitted to the hospital wards. *J Crit Care*. 2015;30(1):78-84.

61. Cross G, Bilgrami I, Eastwood G, et al. The epidemiology of sepsis during rapid response team reviews in a teaching hospital. *Anaesth Intensive Care*. 2015;43(2):193-198.

62. Vincent JL, Marshall JC, Namendys-Silva SA, et al; ICON Investigators. Assessment of the worldwide burden of critical illness. *Lancet Respir Med*. 2014;2(5):380-386.

63. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis. *Crit Care Med*. 2014;42(3):625-631.

64. Koupetori M, Retsas T, Antonakos N, et al; Hellenic Sepsis Study Group. Bloodstream infections and sepsis in Greece. *BMC Infect Dis*. 2014;14:272.

65. Bouza C, López-Cuadrado T, Saz-Parkinson Z, Amate-Blanco JM. Epidemiology and recent trends of severe sepsis in Spain. *BMC Infect Dis*. 2014;14:3863.

66. Storgaard M, Hallas J, Gahrn-Hansen B, et al. Short- and long-term mortality in patients with community-acquired severe sepsis and septic shock. *Scand J Infect Dis*. 2013;45(8):577-583.

67. Stiermaier T, Herkner H, Tobudic S, et al. Incidence and long-term outcome of sepsis on general wards and in an ICU at the General Hospital of Vienna: an observational cohort study. *Wien Klin Wochenschr*. 2013;125(11-12):302-308.

68. Rohde JM, Odden AJ, Bonham C, et al. The epidemiology of acute organ system dysfunction from severe sepsis outside of the intensive care unit. *J Hosp Med*. 2013;8(5):243-247.

69. Gray A, Ward K, Lees F, et al. The epidemiology of adults with severe sepsis and septic shock in Scottish emergency departments. *Emerg Med J*. 2013;30(5):397-401.

70. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of

severe sepsis in the United States. *Crit Care Med*. 2013;41(5):1167-1174.

71. Czupryna P, Garkowski A, Moniuszko A, et al. Patients with sepsis in infectious diseases department in years 1997-2010—epidemiology and clinical features. *Przegl Epidemiol*. 2013;67(3):429-434.

72. Seymour CW, Rea TD, Kahn JM, Walkey AJ, Yealy DM, Angus DC. Severe sepsis in pre-hospital emergency care. *Am J Respir Crit Care Med*. 2012;186(12):1264-1271.

73. Sancho S, Artero A, Zaragoza R, et al. Impact of nosocomial polymicrobial bloodstream infections on the outcome in critically ill patients. *Eur J Clin Microbiol Infect Dis*. 2012;31(8):1791-1796.

74. Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. *Crit Care Med*. 2012;40(3):754-761.

75. Bastani A, Galens S, Rocchini A, et al. ED identification of patients with severe sepsis/septic shock decreases mortality in a community hospital. *Am J Emerg Med*. 2012;30(8):1561-1566.

76. Vesteinsdottir E, Karason S, Sigurdsson SE, et al. Severe sepsis and septic shock: a prospective population-based study in Icelandic intensive care units. *Acta Anaesthesiol Scand*. 2011;55(6):722-731.

77. Rosado V, Pérez L, Guerra H, et al. Outcomes associated with conventional management of severe sepsis at Damas Hospital. *Bol Asoc Med P R*. 2011;103(2):35-38.

78. Davis JS, Cheng AC, McMillan M, Humphrey AB, Stephens DP, Anstey NM. Sepsis in the tropical Top End of Australia's Northern Territory. *Med J Aust*. 2011;194(10):519-524.

79. Wilhelms SB, Huss FR, Granath G, Sjöberg F. Assessment of incidence of severe sepsis in Sweden using different ways of abstracting *International Classification of Diseases* codes. *Crit Care Med*. 2010;38(6):1442-1449.

80. Shen HN, Lu CL, Yang HH. Epidemiologic trend of severe sepsis in Taiwan from 1997 through 2006. *Chest*. 2010;138(2):298-304.

81. Husak L, Marcuzzi A, Herring J, et al. National analysis of sepsis hospitalizations and factors contributing to sepsis in-hospital mortality in Canada. *Healthc Q*. 2010;13(Spec No):35-41.

82. Bateman BT, Schmidt U, Berman MF, Bittner EA. Temporal trends in the epidemiology of severe postoperative sepsis after elective surgery. *Anesthesiology*. 2010;112(4):917-925.

83. Vogel TR, Dombrovskiy VY, Lowry SF. Trends in postoperative sepsis: are we improving outcomes? *Surg Infect (Larchmt)*. 2009;10(1):71-78.

84. Beale R, Reinhart K, Brunkhorst FM, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. *Infection*. 2009;37(3):222-232.

85. Baharoon S, Al-Jahdali H, Al Hashmi J, Memish ZA, Ahmed QA. Severe sepsis and septic shock at the Hajj. *Travel Med Infect Dis*. 2009;7(4):247-252.

86. Rezende E, Silva JM Jr, Isola AM, et al. Epidemiology of severe sepsis in the emergency department and difficulties in the initial assistance. *Clinics (Sao Paulo)*. 2008;63(4):457-464.

87. Blanco J, Muriel-Bombín A, Sagredo V, et al; Grupo de Estudios y Análisis en Cuidados Intensivos. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. *Crit Care*. 2008;12(6):R158.

88. Beovic B, Hladnik Z, Pozenel P, Siuka D; Slovenian Severe Sepsis Study Group. Epidemiology of severe sepsis in Slovenian intensive care units for adults. *J Chemother*. 2008;20(1):134-136.

89. Andreu Ballester JC, Ballester F, González Sánchez A, et al. Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004. *Infect Control Hosp Epidemiol*. 2008;29(7):630-634.

90. Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United States emergency departments. *Crit Care Med*. 2007;35(8):1928-1936.

91. Cheng B, Xie G, Yao S, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. *Crit Care Med*. 2007;35(11):2538-2546.

92. Tanriover MD, Guven GS, Sen D, Unal S, Uzun O. Epidemiology and outcome of sepsis in a tertiary-care hospital in a developing country. *Epidemiol Infect*. 2006;134(2):315-322.

93. Strehlow MC, Emond SD, Shapiro NI, Pelletier AJ, Camargo CA Jr. National study of emergency department visits for sepsis, 1992 to 2001. *Ann Emerg Med*. 2006;48(3):326-331.

94. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004. *Crit Care*. 2006;10(2):R42.

95. Záhorec R, Firment J, Straková J, et al. Epidemiology of severe sepsis in intensive care units in the Slovak Republic. *Infection*. 2005;33(3):122-128.

96. Sundararajan V, Macisaac CM, Presneill JJ, Cade JF, Visvanathan K. Epidemiology of sepsis in Victoria, Australia. *Crit Care Med*. 2005;33(1):71-80.

97. Adrie C, Alberti C, Chaix-Couturier C, et al. Epidemiology and economic evaluation of severe sepsis in France. *J Crit Care*. 2005;20(1):46-58.

98. van Gestel A, Bakker J, Veraart CP, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. *Crit Care*. 2004;8(4):R153-R162.

99. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. *Intensive Care Med*. 2004;30(4):589-596.

100. Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med*. 2004;30(4):580-588.

101. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. *Crit Care Med*. 2003;31(9):2332-2338.

102. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*. 2003;348(16):1546-1554.

103. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med*. 2001;29(7):1303-1310.

104. Wichmann MW, Inthorn D, Andress HJ, Schildberg FW. Incidence and mortality of severe sepsis in surgical intensive care patients. *Intensive Care Med*. 2000;26(2):167-172.

105. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. *JAMA*. 1997;278(3):234-240.

106. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW. Long-term survival after intensive care unit admission with sepsis. *Crit Care Med*. 1995;23(6):1040-1047.

107. Brun-Buisson C, Doyon F, Carlet J, et al; French ICU Group for Severe Sepsis. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. *JAMA*. 1995;274(12):968-974.

108. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. *Virulence*. 2014;5(1):4-11.

109. Moss M, Martin GS. A global perspective on the epidemiology of sepsis. *Intensive Care Med*. 2004;30(4):527-529.

110. Linde-Zwirble WT, Angus DC. Severe sepsis epidemiology: sampling, selection, and society. *Crit Care*. 2004;8(4):222-226.

111. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med*. 2013;41(2):580-637.

112. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med*. 2001;344(10):699-709.

113. Vincent JL, Moreno R, Takala J, et al; Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. *Intensive Care Med*. 1996;22(7):707-710.

114. Li P, Stuart EA, Allison DB. Multiple imputation: a flexible tool for handling missing data. *JAMA*. 2015;314(18):1966-1967.

115. Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. *Crit Care Med*. 2009;37(5):1670-1677.

116. Vincent JL, Ince C, Bakker J. Clinical review: Circulatory shock—an update: a tribute to Professor Max Harry Weil. *Crit Care*. 2012;16(6):239.

117. Nichol AD, Egi M, Pettila V, et al. Relative hyperlactatemia and hospital mortality in critically ill patients. *Crit Care*. 2010;14(1):R25.

118. Levy B, Gibot S, Franck P, Cravoisy A, Bollaert PE. Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock. *Lancet*. 2005;365(9462):871-875.

119. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. *Crit Care*. 2014;18(5):503.

120. Grimes DA, Schulz KF. Bias and causal associations in observational research. *Lancet*. 2002;359(9302):248-252.